Law firm investigates GeneDx after shares plunge 50% on weak earnings and lowered guidance

GeneDx faces securities fraud probe after missing revenue targets and stock plunges 49%.

Pomerantz LLP is investigating GeneDx Holdings Corp. for potential securities fraud after the company reported lower-than-expected Q1 2026 revenue and cut its full-year guidance. Despite 34% growth in test volumes, revenue growth lagged at 27%, with ...